23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Nektar Therapeutics › 2025-2026

Nektar Therapeutics 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Nektar Therapeutics’s Form 8-K, filed June 5, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 4Ballot items
  • 179Asset managers, any item
  • 577Fund votes
  • June 4, 2026Meeting date

Results at a glance

Meeting of June 4, 2026: 4 items on Nektar Therapeutics’s Form 8-K, filed June 5, 2026: 3 approved · 1 passed (calculated).

Dissent

Significant dissent: 1 director (27.4% against); 1 equity or compensation plan (27.1% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Two Seas Capital LP (13F, 9.8%, as of September 30, 2026)

Explore Nektar Therapeutics in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Nektar Therapeutics

These tallies are Nektar Therapeutics’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 5, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Nektar Therapeutics — official shareholder meeting results, meeting held June 4, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Howard W. Robin 13,164,8794,975,288286,175 --4,588,835 73%Passed (calculated)—
2. Proposal to approve an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance thereunder by 3,000,000 shares 13,160,6614,902,925362,756 --4,588,835 73%Approved—
3. Proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 22,591,556118,592305,029 --0 99.5%Approved—
4. Proposal to approve the non-binding advisory resolution regarding our executive compensation 18,154,226161,005111,111 --4,588,835 99.1%Approved—

This meeting is also recorded here as June 5, 2026; both records come from the same filing, so the date should be checked against it.

Source: Nektar Therapeutics, Form 8-K, filed with the SEC on June 5, 2026 — read the filing on EDGAR.

How asset managers voted at the Nektar Therapeutics 2025-2026 meeting

179 asset managers disclosed a vote on at least one Nektar Therapeutics item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Howard W. Robin

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

73% Majority: yes · of votes cast

FOR 73%AGAINST
FOR: 13,164,879AGAINST: 4,975,288
Details: description as filed, official tally, votes by 38 asset managers

Description as filed by funds: Election of Directors: Howard W. Robin

Nektar Therapeutics’s own tally for this item (“Elect Director: Howard W. Robin”): 13,164,879 for, 4,975,288 against, per its Form 8-K filed June 5, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 73% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 38 asset managers below reported 3,036,968 for, 2,695,051 against, 1 abstained.

FORAGAINST
FOR: 3,036,968AGAINST: 2,695,051ABSTAIN: 1
Largest asset managers voting on “Election of Directors: Howard W. Robin” at Nektar Therapeutics, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity299,6562,436,304 00Mixed
Vanguard1,252,2872,368 10For
Invesco353,9930 00For
PRIMECAP Odyssey Funds246,6340 00For
Lord Abbett234,8450 00For
Charles Schwab168,1040 00For
RBB FUND, INC.499165,939 00Against
Principal090,281 00Against
DWS90,0000 00For
BlackRock83,5780 00For
State Street73,36153 00For
Russell Investments60,1500 00For
MassMutual42,0370 00For
Equitable26,7430 00For
ALGER FUNDS19,0350 00For
Delaware/Macquarie17,0920 00For
ALGER FUNDS II10,4310 00For
Morgan Stanley10,3940 00For
MML Series Investment Fund II10,2210 00For
Empower8,6460 00For
Blackstone Alternative Investment Funds4,7600 00For
ETFis Series Trust I4,7480 00For
T. Rowe Price4,0000 00For
ProShares3,1590 00For
Victory Capital3,1270 00For

Showing the 25 largest of 38 asset managers. All 38 are in the interactive database (link above).

Proposal to approve an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate…

Official resultCOMPENSATIONReported outcome: Approved

Combines 2 wordings of this item as funds reported it.

73% Approved · of votes cast

FOR 73%AGAINST
FOR: 13,160,661AGAINST: 4,902,925
Details: description as filed, official tally, votes by 41 asset managers

Description as filed by funds: TO APPROVE AN AMENDMENT TO OUR AMENDED AND RESTATED 2017 PERFORMANCE INCENTIVE PLAN TO INCREASE THE AGGREGATE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE UNDER THE PLAN BY 3,000,000 SHARES.

Nektar Therapeutics’s own tally for this item (“2. Proposal to approve an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance thereunder by 3,000,000 shares”): 13,160,661 for, 4,902,925 against — passed, per its Form 8-K filed June 5, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2 The proposal to approve an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of common stock authorized for issuance thereunder by 3,000,000 shares was approved with the following votes.”
Support: 73% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 41 asset managers below reported 3,321,502 for, 2,446,530 against, 1 abstained.

FORAGAINST
FOR: 3,321,502AGAINST: 2,446,530ABSTAIN: 1
Largest asset managers voting on “TO APPROVE AN AMENDMENT TO OUR AMENDED AND RESTATED 2017 PERFORMANCE INCENTIVE PLAN TO INCREASE THE AGGREGATE ” at Nektar Therapeutics, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity299,6562,436,304 00Mixed
Vanguard1,252,2872,367 10For
Invesco353,9930 00For
PRIMECAP Odyssey Funds246,6340 00For
Lord Abbett234,8450 00For
Charles Schwab168,1040 00For
RBB FUND, INC.165,939499 00For
Principal90,2810 00For
DWS90,0000 00For
BlackRock83,5780 00For
State Street73,36153 00For
Russell Investments60,1500 00For
MassMutual42,0370 00For
IRIDIAN ASSET MANAGEMENT LLC/CT31,3200 00For
Equitable26,7430 00For
ALGER FUNDS19,0350 00For
Delaware/Macquarie17,0920 00For
ALGER FUNDS II10,4310 00For
Morgan Stanley10,3940 00For
MML Series Investment Fund II10,2210 00For
Empower8,6460 00For
Blackstone Alternative Investment Funds4,7600 00For
ETFis Series Trust I4,7480 00For
UNITED CAPITAL FINANCIAL ADVISORS, LLC04,680 00Against
T. Rowe Price4,0000 00For

Showing the 25 largest of 41 asset managers. All 41 are in the interactive database (link above).

Proposal to approve the non-binding advisory resolution regarding our executive compensation

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Combines 7 wordings of this item as funds reported it.

99.1% Approved · of votes cast

FOR 99.1%
FOR: 18,154,226AGAINST: 161,005

Prior year: 96.0% for (May 23, 2025 meeting) ▲ 3.2 pts

Details: description as filed, official tally, votes by 176 asset managers

Description as filed by funds: To approve a non-binding advisory resolution regarding our executive compensation (a "say-on-pay" vote).

Nektar Therapeutics’s own tally for this item (“4. Proposal to approve the non-binding advisory resolution regarding our executive compensation”): 18,154,226 for, 161,005 against — passed, per its Form 8-K filed June 5, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 4 The proposal to approve the non-binding advisory resolution regarding our executive compensation was approved with the following votes.”
Support: 99.1% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Also reported under other wordings, matched to the same row of Nektar Therapeutics’s official tally and shown with their own fund figures; their managers are not in the figures or the table on this card: “Advisory Vote to Ratify Named Executive Officers' Compensation” (3 managers, 1,255 for, 3,057 abstained).

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 37 asset managers voting on “To approve a non-binding advisory resolution regarding our executive compensation (a "say-on-pay" vote).” at Nektar Therapeutics, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity2,735,9600 00For
Vanguard1,254,6550 00For
Invesco353,9930 00For
PRIMECAP Odyssey Funds246,6340 00For
Lord Abbett234,8450 00For
Charles Schwab168,1040 00For
RBB FUND, INC.166,4380 00For
Principal90,2810 00For
DWS90,0000 00For
BlackRock83,5780 00For
State Street73,4140 00For
Russell Investments60,1500 00For
MassMutual42,0370 00For
Equitable26,7430 00For
ALGER FUNDS19,0350 00For
Delaware/Macquarie17,0920 00For
ALGER FUNDS II10,4310 00For
Morgan Stanley10,3940 00For
MML Series Investment Fund II10,2210 00For
Empower8,6460 00For
Blackstone Alternative Investment Funds4,7600 00For
ETFis Series Trust I4,7480 00For
T. Rowe Price4,0000 00For
ProShares3,1590 00For
Victory Capital3,1270 00For

Fund voting reports, all 37 managers: 5,731,843 for, 21 against. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 152 asset managers voting on “To approve a non-binding advisory resolution regarding our executive compensation (a "say-on-pay" vote).” at Nektar Therapeutics, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity4,301,6170 00For
BVF INC/IL2,559,5950 00For
Two Seas Capital LP1,991,0460 00For
GREAT POINT PARTNERS LLC550,0000 00For
BlackRock465,8360 00For
Invesco454,3260 00For
Woodline Partners LP407,2780 00For
GEODE CAPITAL MANAGEMENT, LLC351,8490 00For
LORD, ABBETT & CO. LLC330,4490 00For
PRIMECAP MANAGEMENT CO/CA/279,1500 00For
Two Sigma274,3470 00For
Vestal Point Capital, LP257,4180 00For
Prosight Management, LP233,1150 00For
State Street229,9090 00For
Sofinnova Investments, Inc.225,0400 00For
Vanguard205,8420 00For
ORBIMED ADVISORS LLC196,9000 00For
BRAIDWELL LP193,3350 00For
EMERALD ADVISERS, LLC181,1820 00For
Charles Schwab168,1150 00For
DAFNA Capital Management LLC165,1780 00For
Citadel164,6940 00For
Tetragon Partners GP Ltd103,0370 00For
EMERALD MUTUAL FUND ADVISERS TRUST100,6230 00For
Russell Investments99,1020 00For

Institutional-manager reports, all 152 managers: 15,502,011 for, 29,240 against, 3,068 abstained, 10,000 not voted. Showing the 25 largest; every one is in the interactive database (link above).

Proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm…

Official resultAUDIT-RELATEDReported outcome: Approved

99.5% Approved · of votes cast

FOR 99.5%
FOR: 22,591,556AGAINST: 118,592

Prior year: 98.9% for (May 23, 2025 meeting) ▲ 0.6 pts

Details: description as filed, official tally, votes by 38 asset managers

Description as filed by funds: TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

Nektar Therapeutics’s own tally for this item (“3. Proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 22,591,556 for, 118,592 against — passed, per its Form 8-K filed June 5, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3 The proposal to ratify the selection of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was approved with the following votes.”
Support: 99.5% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 38 asset managers below reported 5,730,768 for, 1,250 against, 1 abstained.

FOR
FOR: 5,730,768AGAINST: 1,250ABSTAIN: 1
Largest asset managers voting on “TO RATIFY THE SELECTION OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISC” at Nektar Therapeutics, 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity2,735,9600 00For
Vanguard1,253,5241,130 10For
Invesco353,9930 00For
PRIMECAP Odyssey Funds246,6340 00For
Lord Abbett234,8450 00For
Charles Schwab168,1040 00For
RBB FUND, INC.166,4380 00For
Principal90,2810 00For
DWS90,0000 00For
BlackRock83,5780 00For
State Street73,40212 00For
Russell Investments60,1500 00For
MassMutual42,0370 00For
Equitable26,7430 00For
ALGER FUNDS19,0350 00For
Delaware/Macquarie17,0920 00For
ALGER FUNDS II10,4310 00For
Morgan Stanley10,3940 00For
MML Series Investment Fund II10,2210 00For
Empower8,6460 00For
Blackstone Alternative Investment Funds4,7600 00For
ETFis Series Trust I4,7480 00For
T. Rowe Price4,0000 00For
ProShares3,1590 00For
Victory Capital3,1270 00For

Showing the 25 largest of 38 asset managers. All 38 are in the interactive database (link above).

Largest Nektar Therapeutics shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 33,786,032 shares outstanding at the time of that meeting.

Fund voting reports: top Nektar Therapeutics shareholders by shares voted on “To approve a non-binding advisory resolution regarding our executive compensation (a…”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 8.10%
2Vanguard 3.71%
3Invesco 1.05%
4PRIMECAP Odyssey Funds 0.73%
5Lord Abbett 0.70%
6Charles Schwab 0.50%
7RBB FUND, INC. 0.49%
8Principal 0.27%
9DWS 0.27%
10BlackRock 0.25%
Institutional-manager reports: top Nektar Therapeutics shareholders by shares voted on “To approve a non-binding advisory resolution regarding our executive compensation (a…”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 12.73%
2BVF INC/IL 7.58%
3Two Seas Capital LP 5.89%
4GREAT POINT PARTNERS LLC 1.63%
5BlackRock 1.38%
6Invesco 1.34%
7Woodline Partners LP 1.21%
8GEODE CAPITAL MANAGEMENT, LLC 1.04%
9LORD, ABBETT & CO. LLC 0.98%
10PRIMECAP MANAGEMENT CO/CA/ 0.83%

Reported Nektar Therapeutics holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Nektar Therapeutics holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
FMR (Fidelity)4,303,188 12.74%Form 13F, quarter ended March 31, 2026
FMR LLC3,036,761 8.99%Proxy statement (DEF 14A), proxy filed April 24, 2026
BVF PARTNERS L P/IL2,391,075 7.08%Schedule 13G, filed August 14, 2026
Entities affiliated with Two Seas Global (Master) Fund LP1,959,178 5.80%Proxy statement (DEF 14A), proxy filed April 24, 2026
Entities affiliated with BVF Inc.1,276,595 3.78%Proxy statement (DEF 14A), proxy filed April 24, 2026
Vanguard Group1,027,089 3.04%Form 13F, quarter ended March 31, 2026
Two Sigma930,741 2.75%Form 13F, quarter ended March 31, 2026
G1 Execution Services, LLC809,967 2.40%Schedule 13G, filed February 13, 2026
BlackRock692,650 2.05%Form 13F, quarter ended March 31, 2026
Citadel Advisors665,431 1.97%Form 13F, quarter ended March 31, 2026

Percentages above are of 33,786,032 shares outstanding, as reported by Nektar Therapeutics on its Form 10-Q dated May 1, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Nektar Therapeutics's shareholder meeting held June 4, 2026, in the 2025-2026 proxy season, 179 asset managers reported votes on at least one of its 4 ballot items in their SEC Form N-PX filings, covering 577 separate fund positions. On the most widely held item on that ballot — To approve a non-binding advisory resolution regarding our executive compensation (a… — Nektar Therapeutics's filing reports the proposal as approved, with 99.1% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Nektar Therapeutics's Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 5, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Nektar Therapeutics’s 10-Q dated May 1, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Nektar Therapeutics proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Nektar Therapeutics (NKTR) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/nektar-therapeutics/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.